|Event:||2017 Marcum MicroCap Conference|
|Date:||Friday, June 16, 2017|
|Time:||12 p.m. EDT|
|Location:||Grand Hyatt - Uris Room - Conference Level, New York, NY|
NEW YORK, June 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced today that it will present at the 2017 Marcum MicroCap Conference being held June 15-16, 2017 in New York, NY. Seth Lederman, M.D., president and chief executive officer of Tonix, will provide an update of Tonix's lead development program, TNX-102 SL * for the treatment of posttraumatic stress disorder (PTSD), and the ongoing Phase 3 HONOR study in military-related PTSD. Details on other Tonix pipeline candidates will also be discussed. Information on the presentation is as follows:
The podium presentation will be webcast live and remain available for 90 days. To access the webcast, please visit the Events tab of the Investor Relations section in Tonix's website at www.tonixpharma.com. *TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication. About TNX-102 SL and the Phase 3 HONOR Study TNX-102 SL is a patented sublingual transmucosal formulation of cyclobenzaprine that is in Phase 3 development. PTSD is a serious condition characterized by chronic disability, inadequate treatment options especially for military-related PTSD, and an overall high utilization of healthcare services that contributes to significant economic burdens. In a Phase 2 study, TNX-102 SL 5.6 mg was found to be effective in treating military-related PTSD, which formed the basis of the Breakthrough Therapy designation granted by the FDA. Tonix is currently conducting a Phase 3 trial of TNX-102 SL in military-related PTSD in the United States, the HONOR study, which is a 12-week randomized, double-blind, placebo-controlled trial evaluating the efficacy of TNX-102 SL 5.6 mg in participants with military-related PTSD. This two-arm, adaptive-design trial is targeting enrollment of up to approximately 550 participants across approximately 35 clinical sites. An unblinded interim analysis will be conducted once the study has accumulated efficacy results from approximately 275 randomized participants. In a recent Cross-disciplinary Breakthrough meeting, the FDA confirmed that a single-study new drug application (NDA) approval could be possible if the topline data from the HONOR study are statistically very persuasive. Additional details of the HONOR study are available at www.thehonorstudy.com or https://clinicaltrials.gov/ct2/show/NCT03062540. The U.S. Patent and Trademark Office has issued a patent (U.S. Patent No. 9,636,408) protecting the composition and manufacture of the unique TNX-102 SL formulation. The Protectic™ protective eutectic and Angstro-Technology™ formulation claimed in the patent are important elements of Tonix's proprietary TNX-102 SL composition. This patent is expected to provide TNX-102 SL, upon NDA approval, with U.S. market exclusivity until 2034. About Tonix Pharmaceuticals Holding Corp. Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to TNX-102 SL for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage designed as a daytime treatment for PTSD, and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.